IgD multiple myeloma. A report of three cases

Area of Science:

• Hematology
• Oncology

Background:

• IgD myeloma is a rare and aggressive variant of multiple myeloma.
• Limited data exists on prognostic factors influencing survival in IgD myeloma patients.

Purpose of the Study:

• To retrospectively analyze clinical and laboratory features in IgD myeloma patients.
• To identify potential relationships between these features and patient survival time.

Main Methods:

• Retrospective analysis of three IgD myeloma patients.
• Patients received Melphalan and Prednisone (MP) chemotherapy, with one also receiving interferon alpha.
• Disease monitoring included serum M component, Bence Jones proteinuria, and survival duration (8-52 months).

Main Results:

• All patients achieved a significant response to MP chemotherapy.
• Survival duration varied, with one patient dying at 8 months and two surviving 8 and 52 months.
• Elevated Lactate Dehydrogenase (LDH) levels showed a potential correlation with shorter survival trends.

Conclusions:

• IgD myeloma exhibits unique clinical and laboratory characteristics.
• Standard chemotherapy can induce remission, but some cases may indicate aggressive disease kinetics.
• New prognostic indices are crucial for identifying patients who could benefit from alternative chemotherapy regimens.